149 related articles for article (PubMed ID: 30581091)
21. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer.
Kelly LM; Barila G; Liu P; Evdokimova VN; Trivedi S; Panebianco F; Gandhi M; Carty SE; Hodak SP; Luo J; Dacic S; Yu YP; Nikiforova MN; Ferris RL; Altschuler DL; Nikiforov YE
Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4233-8. PubMed ID: 24613930
[TBL] [Abstract][Full Text] [Related]
22. GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
Jiang J; Wu X; Tong X; Wei W; Chen A; Wang X; Shao YW; Huang J
Lung Cancer; 2018 Jan; 115():5-11. PubMed ID: 29290262
[TBL] [Abstract][Full Text] [Related]
23. VIT-ALK, a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
Hu S; Li Q; Peng W; Feng C; Zhang S; Li C
J Thorac Oncol; 2018 May; 13(5):e72-e74. PubMed ID: 29703539
[No Abstract] [Full Text] [Related]
24. Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene.
Kusano H; Togashi Y; Akiba J; Moriya F; Baba K; Matsuzaki N; Yuba Y; Shiraishi Y; Kanamaru H; Kuroda N; Sakata S; Takeuchi K; Yano H
Am J Surg Pathol; 2016 Jun; 40(6):761-9. PubMed ID: 26848800
[TBL] [Abstract][Full Text] [Related]
25. Integrative analysis of oncogenic fusion genes and their functional impact in colorectal cancer.
Choi Y; Kwon CH; Lee SJ; Park J; Shin JY; Park DY
Br J Cancer; 2018 Jul; 119(2):230-240. PubMed ID: 29955133
[TBL] [Abstract][Full Text] [Related]
26. Identification of a novel LRRC4C-ALK fusion in lung adenocarcinoma and outcome of the response to anaplastic lymphoma kinase inhibitors.
Wang H; Li Z; Qi X; Wang W; Lin Y
J Gene Med; 2021 Mar; 23(3):e3316. PubMed ID: 33559138
[No Abstract] [Full Text] [Related]
27. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
[TBL] [Abstract][Full Text] [Related]
28. A Rare Fusion of CLIP1 and ALK in a Case of Non-Small-Cell Lung Cancer With Neuroendocrine Features.
Pinsolle J; Mondet J; Duruisseaux M; d'Alnoncourt S; Magnat N; de Fraipont F; Moro-Sibilot D; Toffart AC; Brambilla E; McLeer-Florin A
Clin Lung Cancer; 2019 Sep; 20(5):e535-e540. PubMed ID: 31171381
[No Abstract] [Full Text] [Related]
29. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
[TBL] [Abstract][Full Text] [Related]
30. Lung adenocarcinoma during pregnancy: clinical case and literature review.
Bellido C; Barbero P; Forcén L; Blanco M; Alonso-Riaño M; Galindo A
J Matern Fetal Neonatal Med; 2019 Oct; 32(19):3300-3302. PubMed ID: 29618241
[TBL] [Abstract][Full Text] [Related]
31.
Gerthofer V; Scheiter A; Lüke F; Keil F; Utpatel K; Pöhmerer LM; Seitz J; Niessen C; Ignatov A; Dietmaier W; Calvisi DF; Evert M; Ortmann O; Seitz S
JCO Precis Oncol; 2021; 5():. PubMed ID: 34568722
[No Abstract] [Full Text] [Related]
32. RAS signaling in ALK fusion lung cancer.
Hrustanovic G; Bivona TG
Small GTPases; 2016; 7(1):32-3. PubMed ID: 26901483
[TBL] [Abstract][Full Text] [Related]
33. ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases.
Fares AF; Lok BH; Zhang T; Cabanero M; Lau SCM; Stockley T; Patel D; Bradbury PA; Sacher A; Yasufuku K; Morash BA; Sabatini PJB; Nguyen LN; Leighl NB; Tsao MS; Shepherd FA; Liu G; Martins-Filho SN; Pal P
Lung Cancer; 2020 Aug; 146():350-354. PubMed ID: 32546380
[No Abstract] [Full Text] [Related]
34. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
[TBL] [Abstract][Full Text] [Related]
35. OFCC1-ALK (Ointergenic: A20): A novel OFCC1 intergenic region-ALK fusion identified from a lung adenocarcinoma patient.
Zhai X; Wu Q; Zeng Z; Suo J; Lin F; Zhou Q
Lung Cancer; 2021 Mar; 153():171-173. PubMed ID: 33483163
[No Abstract] [Full Text] [Related]
36. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
37. Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing.
Zhu YC; Wang WX; Xu CW; Zhang QX; Du KQ; Chen G; Lv TF; Song Y
Ann Oncol; 2018 Dec; 29(12):2392-2393. PubMed ID: 30339198
[No Abstract] [Full Text] [Related]
38. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
39. Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel
Shimizu N; Akashi Y; Fujii T; Shiono H; Yane K; Kitahara T; Ohta Y; Kakudo K; Wakasa T
Anticancer Res; 2019 Jan; 39(1):413-420. PubMed ID: 30591488
[TBL] [Abstract][Full Text] [Related]
40. Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling.
Ou SH; Chalmers ZR; Azada MC; Ross JS; Stephens PJ; Ali SM; Miller VA
Lung Cancer; 2015 Jun; 88(3):352-4. PubMed ID: 25851827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
